Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22462019 | 0.86 | NNMT (0.46) | NNMTALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL20606047 | 0.82 | ALDH1A1 (0.34) | NNMTALDH1A1KDM4EERN1KMT2A | |
| SCHEMBL26118926 | 0.81 | NNMT (0.54) | NNMTALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL30570813 | 0.81 | NNMT (0.54) | NNMTALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL29775020 | 0.81 | KDM4E (0.40) | ALDH1A1KDM4EERN1POLBRAB9A | |
| SCHEMBL22448711 | 0.81 | NNMT (0.44) | NNMTALDH1A1KDM4EERN1KMT2A | |
| SCHEMBL20907179 | 0.81 | ALDH1A1 (0.33) | NNMTALDH1A1ERN1KMT2AL3MBTL1 | |
| SCHEMBL4982191 | 0.78 | NNMT (0.51) | NNMTALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL21040324 | 0.78 | NNMT (0.70) | NNMTALDH1A1KDM4EKMT2AL3MBTL1 | |
| SCHEMBL17131026 | 0.77 | NNMT (0.44) | NNMTALDH1A1KDM4EKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| CN-119365449-A | Compound used as WDR5 inhibitor or pharmaceutically acceptable salt thereof and application thereof | 甘李药业股份有限公司 | 2025-01-24 | — | — | CN | disclosed |
| WO-2024002379-A1 | COMPOUND USED AS WDR5 INHIBITOR OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE OF COMPOUND | 甘李药业股份有限公司 | 2024-01-04 | — | — | WO | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| CN-109195965-B | Inhibitors of WDR5 protein-protein binding | 普罗佩纶治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| US-9527875-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2015-07-09 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-13 | — | — | US | disclosed |
| WO-2014019186-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014022528-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
| WO-2014019186-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | NNMT 887/4885ALDH1A1 3236/4885KDM4E 217/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | NNMT 887/4885ALDH1A1 3236/4885KDM4E 217/4885 |
| US-20140045746-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | NNMT 3303/4885ALDH1A1 3081/4885KDM4E 3958/4885 |
| US-20150191495-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | NNMT 3303/4885ALDH1A1 3081/4885KDM4E 3958/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | NNMT 887/4885ALDH1A1 3236/4885KDM4E 217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.